Departamento de Ciências Farmacêuticas Centro de Ciências da Saúde, Universidade Federal de Pernambuco, 50740-535, Recife, PE, Brazil.
Laboratório de Prospecção de Moléculas Bioativas Programa de Pós-Graduação em Ciência e Tecnologia Ambiental para o Semiárido, Universidade de Pernambuco, 56328-903, Petrolina, PE, Brazil.
ChemMedChem. 2020 Nov 18;15(22):2164-2175. doi: 10.1002/cmdc.202000331. Epub 2020 Oct 19.
Chagas disease and malaria are two neglected tropical diseases (NTDs) that prevail in tropical and subtropical regions in 149 countries. Chagas is also present in Europe, the US and Australia due to immigration of asymptomatic infected individuals. In the absence of an effective vaccine, the control of both diseases relies on chemotherapy. However, the emergence of parasite drug resistance is rendering currently available drugs obsolete. Hence, it is crucial to develop new molecules. Phthalimides, thiosemicarbazones, and 1,3-thiazoles have been used as scaffolds to obtain antiplasmodial and anti-Trypanosoma cruzi agents. Herein we present the synthesis of 24 phthalimido-thiosemicarbazones (3 a-x) and 14 phthalimido-thiazoles (4 a-n) and the corresponding biological activity against T. cruzi, Plasmodium falciparum, and cytotoxicity against mammalian cell lines. Some of these compounds showed potent inhibition of T. cruzi at low cytotoxic concentrations in RAW 264.7 cells. The most active compounds, 3 t (IC =3.60 μM), 3 h (IC =3.75 μM), and 4 j (IC =4.48 μM), were more active than the control drug benznidazole (IC =14.6 μM). Overall, the phthalimido-thiosemicarbazone derivatives were more potent than phthalimido-thiazole derivatives against T. cruzi. Flow cytometry assay data showed that compound 4 j was able to induce necrosis and apoptosis in trypomastigotes. Analysis by scanning electron microscopy showed that T. cruzi trypomastigote cells treated with compounds 3 h, 3 t, and 4 j at IC concentrations promoted changes in the shape, flagella, and surface of the parasite body similar to those observed in benznidazole-treated cells. The compounds with the highest antimalarial activity were the phthalimido-thiazoles 4 l (IC =1.2 μM), 4 m (IC =1.7 μM), and 4 n (IC =2.4 μM). Together, these data revealed that phthalimido derivatives possess a dual antiparasitic profile with potential effects against T. cruzi and lead-like characteristics.
恰加斯病和疟疾是两种在 149 个国家的热带和亚热带地区流行的被忽视的热带病(NTDs)。由于无症状感染个体的移民,恰加斯病也存在于欧洲、美国和澳大利亚。由于缺乏有效的疫苗,这两种疾病的控制都依赖于化疗。然而,寄生虫耐药性的出现使得目前可用的药物变得过时。因此,开发新的分子至关重要。邻苯二甲酰亚胺、硫代缩氨基脲和 1,3-噻唑已被用作获得抗疟原虫和抗克氏锥虫药物的支架。在此,我们介绍了 24 个邻苯二甲酰亚胺基硫代缩氨基脲(3a-x)和 14 个邻苯二甲酰亚胺基噻唑(4a-n)的合成及其对克氏锥虫、恶性疟原虫的相应生物活性和对哺乳动物细胞系的细胞毒性。这些化合物中的一些在 RAW 264.7 细胞中显示出对 T. cruzi 的低细胞毒性浓度下的有效抑制。最有效的化合物 3t(IC=3.60μM)、3h(IC=3.75μM)和 4j(IC=4.48μM)比对照药物苯并硝唑(IC=14.6μM)更有效。总的来说,邻苯二甲酰亚胺基硫代缩氨基脲衍生物对 T. cruzi 的活性比邻苯二甲酰亚胺基噻唑衍生物更强。流式细胞术检测数据表明,化合物 4j 能够诱导锥虫的坏死和凋亡。扫描电子显微镜分析表明,在 IC 浓度下用化合物 3h、3t 和 4j 处理的 T. cruzi 锥虫型细胞诱导了寄生虫体形状、鞭毛和表面的变化,类似于用苯并硝唑处理的细胞。具有最高抗疟活性的化合物是邻苯二甲酰亚胺基噻唑 4l(IC=1.2μM)、4m(IC=1.7μM)和 4n(IC=2.4μM)。综上所述,这些数据表明邻苯二甲酰亚胺衍生物具有抗寄生虫的双重特性,可能对 T. cruzi 具有潜在的作用,并具有类似先导化合物的特征。